Why Breztri Isnt Approved For Asthma Treatment?

Breztri is not approved for asthma treatment because it is a triple-combination inhaler designed and tested specifically for chronic obstructive pulmonary disease (COPD), not asthma. The U.S. Food and Drug Administration (FDA) approved Breztri in 2020 for maintenance treatment of COPD, and the manufacturer has not submitted it for an asthma indication. While some of its ingredients are used in asthma medications, the specific combination and dosing have not been proven safe and effective for asthma through the required clinical trials.

What Is Breztri and How Does It Work?

Breztri is a brand-name inhaler that combines three active ingredients in one device. The three drugs are budesonide, glycopyrrolate, and formoterol. Each one targets a different part of the airway problem in COPD.

Budesonide is a corticosteroid that reduces inflammation in the airways. Formoterol is a long-acting bronchodilator that relaxes the muscles around the airways to keep them open. Glycopyrrolate is an anticholinergic bronchodilator that also helps open the airways but works through a different receptor pathway.

This combination is often called “triple therapy” because it delivers three different mechanisms of action at once. For COPD patients, this approach has been shown to improve lung function and reduce exacerbations compared to using only one or two of these drug classes.

Why Breztri Isnt Approved For Asthma Treatment

The core reason Breztri is not approved for asthma is that the clinical trials that led to its approval were conducted exclusively in COPD patients. Regulatory approval requires evidence specific to the condition being treated. A drug that works for COPD does not automatically qualify for asthma.

Asthma and COPD are different diseases with different underlying mechanisms. Asthma is primarily an allergic and inflammatory condition that often involves variable airway obstruction. COPD is a progressive disease usually caused by long-term exposure to irritants like cigarette smoke, leading to permanent lung damage.

The FDA requires separate clinical trials for each indication. The manufacturer, AstraZeneca, has not conducted the necessary phase 3 trials to demonstrate that the triple combination is safe and effective for asthma. Without that data, the FDA cannot approve the drug for asthma use.

Could Breztri Ever Be Approved for Asthma?

It is possible in theory, but it would require new clinical trials. The company would need to study the drug in asthma patients and show it improves outcomes such as asthma control, lung function, or exacerbation rates. These studies would need to be large enough and long enough to establish both efficacy and safety.

There are practical challenges. Asthma is typically well managed with an inhaled corticosteroid plus a long-acting bronchodilator. Adding a third drug, glycopyrrolate, may not provide additional benefit for most asthma patients. The added medication also increases the risk of side effects and the cost of treatment.

Some research has explored triple therapy in asthma, particularly in patients with severe disease who do not respond to standard treatment. Some studies suggest that adding an anticholinergic may help certain patients. However, the evidence is not strong enough to support a broad approval, and no major regulatory agency has approved triple therapy for asthma as of this writing.

What Are the Approved Asthma Treatments?

Standard asthma treatment follows a stepwise approach based on symptom frequency and severity. The foundation is an inhaled corticosteroid (ICS) to control inflammation. Examples include budesonide, fluticasone, and beclomethasone.

For patients who need more control, a long-acting beta-agonist (LABA) is added. This combination is common and has been studied extensively. Examples include budesonide-formoterol (Symbicort) and fluticasone-salmeterol (Advair).

For severe asthma, additional options exist. Biologic medications target specific immune pathways involved in asthma. These include drugs like omalizumab, mepolizumab, and dupilumab. These are given by injection and reserved for patients with specific asthma phenotypes.

Is It Safe to Use Breztri for Asthma Anyway?

No. Using a medication outside its approved indication without medical supervision is not recommended. The dosing, delivery system, and combination of drugs in Breztri were optimized for COPD, not asthma.

There are specific safety concerns. Glycopyrrolate, the anticholinergic component, is not commonly used in asthma treatment. Its long-term safety profile in asthma patients is not well established. There may also be differences in how the drugs are absorbed or cleared in asthma patients compared to COPD patients.

Additionally, using an unapproved medication can delay proper treatment. If you have asthma and are not well controlled on your current medication, you should see a doctor to adjust your treatment plan based on established guidelines, not self-prescribe an off-label inhaler.

What Is the Difference Between Asthma and COPD Medications?

While there is overlap, the medication strategies differ. Asthma treatment focuses on controlling inflammation and preventing attacks. COPD treatment focuses on relieving symptoms and reducing exacerbations in a progressive disease.

Anticholinergics like glycopyrrolate and tiotropium are a mainstay of COPD treatment. They are used less frequently in asthma. When they are used in asthma, it is usually as an add-on therapy for severe cases, and the evidence base is more limited.

The table below summarizes the key differences between the two conditions and their typical medication approaches.

What Should You Do If You Have Asthma and COPD?

Some people have both conditions, a situation called asthma-COPD overlap (ACO). This can complicate treatment because the optimal medication strategy is not always clear.

For patients with ACO, clinicians often use a combination of medications. Inhaled corticosteroids are almost always included because they address the inflammatory component of both diseases. Long-acting bronchodilators are also commonly used.

Triple therapy may be appropriate for some patients with ACO. However, this decision should be made by a pulmonologist or asthma specialist based on individual assessment. It should not be based on general assumptions about the drug class.

If your doctor prescribes Breztri for you, it may be for a COPD diagnosis or as part of an off-label treatment plan for severe asthma or ACO. Ask your doctor why they chose this medication and what evidence supports its use in your specific case.

What Does the Evidence Say About Triple Therapy in Asthma?

The evidence for triple therapy in asthma is limited but not absent. Some small studies have evaluated adding a long-acting muscarinic antagonist (LAMA) like tiotropium to standard ICS-LABA therapy in asthma patients.

Results have been mixed. Some studies show modest improvements in lung function, particularly in patients with poorly controlled asthma. Other studies show no significant benefit over ICS-LABA alone. The effect on asthma exacerbations is even less clear.

No large, definitive trials have confirmed that triple therapy is superior to standard care for the general asthma population. This is why no regulatory agency has approved a triple inhaler for asthma. The potential benefit appears limited to a subset of patients, and identifying that subset reliably is still an open question.

Key Takeaways

Breztri is a COPD medication. It is not approved for asthma because it has not been tested and proven for that use. The FDA requires separate evidence for each condition, and that evidence does not exist for asthma.

Asthma is generally well managed with inhaled corticosteroids and long-acting bronchodilators. Triple therapy is not a standard asthma treatment. If you have questions about your inhaler or your asthma control, talk to your doctor.